400-500 mg PO TID
Prostatitis: 500 mg PO BID
Cancer: 420-1400 mg/sq.meter IV bolus qWeek
Seasonal allergy; prevention of diabetic cataracts; viral infections; CVD
Adjunctive therapy in cancer
Chronic prostatitis, interstitial cystitis
Possibly effective in treatment of nonbacterial chronic prostatitis, interstitial cystitis
Other uses mainly derived from animal studies
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
IV: Nephrotoxicity (>945 mg/sq. meter)
Pregnancy & Lactation
Pregnancy Category: N/A
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Flavonoid found in many foods; anti-inflammatory, antioxidant
Inhibits aldose reductase in lens